Program
ORKA-002
A development code.
Its studies are mostly in Psoriasis · Hidradenitis Suppurativa, led by Oruka Therapeutics.
Furthest: phase 2, since Mar 11, 20264 company-led studies, 3 open or runningNext primary completion: Oct 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Oruka Therapeutics | 43 open or running | phase 2since Mar 11, 2026 | Apr 15, 2025 | Oct 2027phase 2 · NCT07474792 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 15, 2025First study: phase 1 study in Healthy VolunteersFirst studyNCT06944379 · 24 enrolled · New Zealand
- Mar 11, 2026Phase 2 study in Plaque PsoriasisPhase 2 reachedNCT07474792 · 160 enrolled · United States, Canada
- Aug 20, 2026Phase 2 study in Hidradenitis SuppurativaNCT07783542 · 200 planned · United States, Canada
- Nov 5, 2026Phase 2 study in Plaque PsoriasisNCT07933783 · 160 planned · United States, Canada
Ahead
- Oct 2027Primary completion: phase 2 study in Plaque PsoriasisNCT07474792
- Oct 2028Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07783542
- Jul 1, 2029Primary completion: phase 2 study in Plaque PsoriasisNCT07933783
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07933783Plaque Psoriasis · United States, Canada | 2 | By invitation | Jul 1, 2029 | 160 |
| NCT07783542Hidradenitis Suppurativa · United States, Canada | 2 | Recruiting | Oct 2028 | 200 |
| NCT07474792Plaque Psoriasis · United States, Canada | 2 | Active, not recruiting | Oct 2027 | 160 |
| NCT06944379Healthy Volunteers · New Zealand | 1 | Completed | Aug 20, 2026 | 24 |
How it is read
Names in the registry
- “ORKA-002”, 4 entries
Codes read as this program: ORKA002.
Conditions, from the studies’ own filings
- Psoriasis, 2 studies
- Hidradenitis Suppurativa, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.